Bristol-Myers Squibb Co
featured
Stocks are down nearly 1 percent in late trading after the minutes from the last Fed policy setting meeting suggested the central bank could begin tapering bond purchases sooner than the market expects.
» Read More
More
-
Stocks are down nearly 1 percent in late trading after the minutes from the last Fed policy setting meeting suggested the central bank could begin tapering bond purchases sooner than the market expects.
-
*Bernanke touts benefits of Fed easing, but hints could act.
-
Baxter International Inc. rose$. 16 or. 2 percent, to $73.20. Bristol-Myers Squibb Co. rose $3.30 or 7.5 percent, to $47.36. Hospira rose$. 02 or. 1 percent, to $35.94.
-
NEW YORK-- A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. Bank of America Corp. rose 1.4 percent to $13.63 with 88,111,200 shares traded. Barrick Gold Corp. rose 1.8 percent to $19.71 with 16,112,200 shares traded.
-
NEW YORK-- A look at the 10 biggest percentage gainers on New York Stock Exchange at 1 p.m.:. Zale Corp. rose 21.9 percent to $6.58. Saks Inc. rose 16.3 percent to $15.90.
-
*Saks rallies on report it could sell itself. NEW YORK, May 22- U.S. stocks rose on Wednesday, giving up some gains after an initial rally, after Federal Reserve Chairman Ben Bernanke said the central bank needed to see further signs of traction in the economy before it tapered its economic stimulus efforts.
-
Baxter International Inc. rose$. 32 or. 4 percent, to $73.36. Bristol-Myers Squibb Co. rose $2.27 or 5.2 percent, to $46.33. Hospira rose$. 21 or. 6 percent, to $36.13.
-
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease, according to a Citi, which raised its rating on the drugmaker.
-
*Potential sales of $35 bln a year over next 10 years- Citigroup. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.
-
Baxter International Inc. rose$. 10 or. 1 percent, to $73.04. Bristol-Myers Squibb Co. rose$. 30 or. 7 percent, to $44.06. Hospira fell$. 11 or. 3 percent, to $35.92.
-
Baxter International Inc. fell$. 22 or. 3 percent, to $72.72. Bristol-Myers Squibb Co. fell$. 08 or. 2 percent, to $43.68. Hospira rose$. 12 or. 3 percent, to $36.15.
-
Bristol-Myers Squibb Co. rose$. 25 or. 6 percent, to $44.01. Hospira rose$. 15 or. 4 percent, to $36.18. Johnson& Johnson rose$. 15 or. 2 percent, to $88.16.
-
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
-
Bristol-Myers Squibb Co. rose$. 46 or 1.1 percent, to $43.76. Hospira rose$. 29 or. 8 percent, to $36.03. Johnson& Johnson fell$. 08 or. 1 percent, to $88.01.
-
Baxter International Inc. rose$. 80 or 1.1 percent, to $73.74. Bristol-Myers Squibb Co. rose$. 45 or 1.0 percent, to $43.75. Hospira rose$. 17 or. 5 percent, to $35.91.
-
Baxter International Inc. rose$. 26 or. 4 percent, to $73.20. Bristol-Myers Squibb Co. rose$. 59 or 1.4 percent, to $43.89. Hospira rose$. 24 or. 7 percent, to $35.98.
-
Baxter International Inc. rose $1.09 or 1.5 percent, to $72.94. Bristol-Myers Squibb Co. rose$. 53 or 1.2 percent, to $43.30. Hospira rose$. 02 or. 1 percent, to $35.74.
-
Baxter International Inc. rose$. 68 or. 9 percent, to $72.53. Bristol-Myers Squibb Co. rose$. 19 or. 4 percent, to $42.96. Hospira rose$. 06 or. 2 percent, to $35.78.
-
Baxter International Inc. rose$. 99 or 1.4 percent, to $72.84. Bristol-Myers Squibb Co. rose$. 28 or. 7 percent, to $43.05. Hospira rose$. 28 or. 8 percent, to $36.00.
-
Baxter International Inc. rose $1.30 or 1.8 percent, to $71.85. Bristol-Myers Squibb Co. fell $1.57 or 3.5 percent, to $42.77. Hospira rose $1.29 or 3.7 percent, to $35.72.